Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16783535 | 0.75 | PTGES (0.50) | PTGESMAPTALDH1A1KDM4ETYMP | |
| SCHEMBL31179761 | 0.75 | PTGES (0.50) | PTGESMAPTALDH1A1KDM4ETYMP | |
| SCHEMBL18672450 | 0.75 | PTGES (0.50) | PTGESMAPTALDH1A1KDM4ETYMP | |
| SCHEMBL7076064 | 0.74 | AKR1B1 (0.52) | PTGESMAPTALDH1A1KDM4ETYMP | |
| SCHEMBL29006537 | 0.73 | CYP2C9 (0.54) | CYP2C9ALDH1A1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL6174622 | 0.73 | CYP2C9 (0.61) | CYP2C9MAPTALDH1A1KDM4E | |
| SCHEMBL10725654 | 0.73 | MAPT (0.67) | PTGESMAPTALDH1A1KDM4ETYMP | |
| SCHEMBL6601327 | 0.72 | LOXL2 (0.51) | MAPTALDH1A1KDM4ECASP3SENP7 | |
| SCHEMBL9402063 | 0.70 | ELANE (0.54) | PTGESMAPTALDH1A1KDM4ETYMP | |
| SCHEMBL31604207 | 0.70 | PTGES (0.56) | PTGESMAPTALDH1A1KDM4ETYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528806-A1 | PHARMACEUTICAL COMPOUNDS | Sareum Limited (GB) | 2019-08-28 | — | — | EP | claimed |
| WO-2018073438-A1 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2018-04-26 | — | — | WO | claimed |
| EP-3528806-A1 | PHARMACEUTICAL COMPOUNDS | Sareum Limited (GB) | 2019-08-28 | — | — | EP | disclosed |
| WO-2018073438-A1 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2018-04-26 | — | — | WO | disclosed |
| EP-1397350-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | Kudos Pharmaceuticals Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-6664269-B2 | Adminisetring isoquinolinone compounds for therapy of disease mediated by the enzyme poly(ADP- ribose)polymerase (\"PARP\") | MAYBRIDGE PLC (GB) | 2003-12-16 | — | — | US | disclosed |
| WO-2003005969-A2 | TETRAHYDROPURINONES AS CORTICOTROPIN RELEASING FACTOR | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20030008896-A1 | Isoquinolinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2003-01-09 | — | — | US | disclosed |
| WO-2002090334-A1 | ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008896-A1 | Isoquinolinone derivatives | PARP1, PARP2, PARP3 | CYP2C9 3441/4885PTGES 1279/4885MAPT 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.